Furthermore, a preclinical study showed that BRAF inhibition leads to upregulation of a variety of receptor tyrosine kinases in CRC cell lines, including EGFR, HER2 and HER3 [45]. The gene discussed is BRAF; the disease is colorectal carcinoma.